In a sector where a governance failure can cost lives as well as regulatory approval, ‘a human in the loop’ can no longer be viewed as a safety net. In many pharmaceutical businesses, it creates the appearance of oversight without the reality of accountability.
HFS Research, in partnership with Altimetrik, surveyed 505 senior executives across Global 2000 organisations, of which 68 are UK-based, to understand how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms. What the research reveals should give every leader in the pharmaceutical industry pause, because the governance gap it exposes is most dangerous where the consequences of getting it wrong are highest.
Pharma has deployed AI extensively. Across drug discovery, clinical operations, pharmacovigilance, commercial functions and beyond, intelligent systems are already making recommendations that shape consequential decisions. But deployment is not governance. And the distance between the two is widening.
Read the article in full here.